Serum tumour necrosis factor-alpha is associated with poor health-related quality of life and depressive symptoms in patients with systemic lupus erythematosus

Lupus

Volumn 22, Issue 3, 2013, Pages 254-261

  Mak, A ^a   Tang, C S ^a   Ho, R C ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

depression; health related quality of life; Proinflammatory cytokines; systemic lupus erythematosus; tumour necrosis factor alpha

Indexed keywords

AZATHIOPRINE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CYCLOSPORIN; HYDROXYCHLOROQUINE; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 33; INTERLEUKIN 6; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE; ANXIETY DISORDER; ARTICLE; CHINESE; COMPLEMENT BLOOD LEVEL; CONTROLLED STUDY; CORRELATIONAL STUDY; DEPRESSION; DISEASE SEVERITY; EDUCATIONAL STATUS; FEMALE; GENDER; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; INDIAN; MAJOR CLINICAL STUDY; MALAYSIA; MALE; MARRIAGE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOLOGIC ASSESSMENT; QUALITY OF LIFE; SEROLOGY; SHORT FORM 36; SMOKING; STEROID THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; BIOLOGICAL MARKERS; CYTOKINES; DEPRESSION; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; QUALITY OF LIFE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84874422930     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203312471872     Document Type: Article

References (34)

1. Almehed K, Carlsten H, Forsblad-d'Elia H. Health-related quality of life in systemic lupus erythematosus and its association with disease and work disability. Scand J Rheumatol. 2010 ; 39: 58-62
2. Lau CS, Mak A. The socioeconomic burden of SLE. Nat Rev Rheumatol. 2009 ; 5: 400-404
3. Jolly M. How does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illnesses?. J Rheumatol. 2005 ; 32: 1706-1708
4. Panopalis P, Clarke AE. Quality of life in systemic lupus erythematosus. Clin Dev Immunol. 2006 ; 13: 321-324
5. McElhone K, Abbott J, Teh LS. A review of health related quality of life in systemic lupus erythematosus. Lupus. 2006 ; 15: 633-643
6. Mak A, Tang CS, Chan MF, Cheak AA, Ho RC. Damage accrual, cumulative glucocorticoid dose and depression predict anxiety in patients with systemic lupus erythematosus. Clin Rheumatol. 2011 ; 30: 795-803
7. Stoll T, Gordon C, Seifert B, et al. Consistency and validity of patient administered assessment of quality of life by the MOS SF-36; its association with disease activity and damage in patients with systemic lupus erythematosus. J Rheumatol. 1997 ; 24: 1608-1614
8. Strand V, Aranow C, Cardiel MH, et al. Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo. Lupus. 2003 ; 12: 677-686
9. Ranjith G, Pariante C Cytokine stress and immunity. 2 nd ednFlorida: CRC Press, 2007349-358. Plotnikoff NP Faith RE Murgo AJ Good RA, ed. Florida: CRC Press ; 2007: 349-358.
10. Bonaccorso S, Puzella A, Marino V, et al. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res. 2001 ; 105: 45-55
11. Loftis JM, Hauser P. The phenomenology and treatment of interferon-induced depression. J Affect Disord. 2004 ; 82: 175-190
12. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 ; 40: 1725-1725
13. Härter M, Woll S, Wunsch A, Bengel J, Reuter K. Screening for mental disorders in cancer, cardiovascular and musculoskeletal diseases. Comparison of HADS and GHQ-12. Soc Psychiatry Psychiatr Epidemiol. 2006 ; 41: 56-62
14. Thumboo J, Fong KY, Chan SP, et al. A prospective study of factors affecting quality of life in systemic lupus erythematosus. J Rheumatol. 2000 ; 27: 1414-1420
15. Gladman DD, Urowitz MB, Goldsmith CH, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum. 1997 ; 40: 809-813
16. Gladman DD, Goldsmith CH, Urowitz MB, et al. Sensitivity to change of 3 Systemic Lupus Erythematosus Disease Activity Indices: International validation. J Rheumatol. 1994 ; 21: 1468-1471
17. Mok MY, Wu HJ, Lo Y, Lau CS. The relation of interleukin 17 (IL-17) and IL-23 to Th1/Th2 cytokines and disease activity in systemic lupus erythematosus. J Rheumatol. 2010 ; 37: 2046-2052
18. Chun HY, Chung JW, Kim HA, et al. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol. 2007 ; 27: 461-466
19. Mok MY, Huang FP, Ip WK, et al. Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology (Oxford). 2010 ; 49: 520-527
20. Gabay C, Cakir N, Moral F, et al. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol. 1997 ; 24: 303-308
21. Studnicka-Benke A, Steiner G, Petera P, Smolen JS. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol. 1996 ; 35: 1067-1074
22. Field A Discovering statistics using SPSS. Regression. 3 rd edn, London: Sage, 2005197-263. London: Sage ; 2005: 197-263.
23. Sabry A, Elbasyouni SR, Sheashaa HA, et al. Correlation between levels of TNF-alpha and IL-6 and hematological involvement in SLE Egyptian patients with lupus nephritis. Int Urol Nephrol. 2006 ; 38: 731-737
24. Studnicka-Benke A, Steiner G, Petera P, Smolen JS. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol. 1996 ; 35: 1067-1074
25. Arora V, Verma J, Marwah V, Kumar A, Anand D, Das N. Cytokine imbalance in systemic lupus erythematosus: A study on northern Indian subjects. Lupus. 2012 ; 21: 596-603
26. Weckerle CE, Imbuka D, Franek BS, et al. Large scale analysis of tumor necrosis factor alpha levels in systemic lupus erythematosus. Arthritis Rheum. Epub ahead of print 5 April 2012. DOI: 10.1002/art.34483.
27. Weckerle CE, Franek BS, Kelly JA, et al. Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum. 2011 ; 63: 1044-1053
28. Connor TJ, Song C, Leonard BE, Merali Z, Anisman H. An assessment of the effects of central interleukin-1beta, -2, -6, and tumor necrosis factor-alpha administration on some behavioural, neurochemical, endocrine and immune parameters in the rat. Neuroscience. 1998 ; 84: 923-933
29. Carroll BJ. The dexamethasone suppression test for melancholia. Br J Psychiatry. 1982 ; 140: 292-304
30. Myint AM, Kim YK. Cytokine-serotonin interaction through IDO: A neurodegeneration hypothesis of depression. Med Hypotheses. 2003 ; 61: 519-525
31. Zalcman S, Green-Johnson JM, Murray L, et al. Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res. 1994 ; 643: 40-49
32. Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl). 2003 ; 170: 429-433
33. Thomas AJ, Davis S, Morris C, Jackson E, Harrison R, O'Brien JT. Increase in interleukin-1beta in late-life depression. Am J Psychiatry. 2005 ; 162: 175-177
34. Trzonkowski P, Myaliwska J, Godlewska B, et al. Immune consequences of the spontaneous proinflammatory status in depressed elderly patients. Brain Behav Immun. 2004 ; 18: 135-148